Adicet Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Adicet Reports First Quarter 2023 Financial Results And Provides Business Updates
Brief: Adicet Bio posts Q1 basic EPS USD -0.72
Adicet Bio Inc expected to post a loss of 69 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Booking Holdings, FedEx, LivePerson
Adicet Bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: Adicet Reports Q4 And Full Year 2022 Financial Results And Highlights Recent Company Progress
Brief: Adicet Bio Q4 loss per share USD 0.72
Brief: Tang Capital Partners Lp Reports 5.3% Passive Stake In Adicet Bio Inc As Of March 3 - SEC Filing
Adicet Bio Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: EcoR1 Capital Reports 8.3% Passive Stake In Adicet Bio - SEC Filing
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
Brief: Adicet Bio Reports Positive Data From Ongoing Adi-001 Phase 1 Trial In Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin’S Lymphoma (Nhl)
Brief: Adicet Bio Appoints Nancy Boman As Senior Vice President
Adicet Bio Inc reports results for the quarter ended in September - Earnings Summary
Brief: Adicet Bio Inc Files For Common Stock Offering Of Up To $100 Million - SEC Filing
Brief: Adicet Reports Third Quarter 2022 Results
Adicet Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Adicet Bio rises on cancer therapy trial safety, efficacy data